Search Thermo Fisher Scientific
- Contact Us
- Quick Order
-
Don't have an account ? Create Account
Search Thermo Fisher Scientific
Gibco CTS Dynabeads magnetic beads are a trusted technology for the isolation, activation, and/or expansion of T-cells ex vivo. Whether working with polyclonal T-cells, antigen-specific T-cells, gene-modified T-cells, regulatory T-cells, or other T-cell subtypes, CTS Dynabeads magnetic beads enable the recovery of T-cells with properties comparable to in vivo–activated T-cells.
Our Gibco CTS Detachable Dynabeads beads possess a proprietary active release mechanism—the first of its kind for GMP, clinical trial, and commercial manufacturing use. These new offerings are intended for use with the CTS DynaCellect system to achieve its full range of benefits. With its active release mechanism and high specificity, our CTS Detachable Dynabeads platform allows for significant flexibility and scalability of manufacturing processes that vary widely from one therapy to another. Its performance exhibits consistent and optimal isolation, activation, and purity of target T-cell populations while addressing the biological variability that cell therapy manufacturers are facing.
The CTS Detachable Dynabeads beads are based on our existing paramagnetic bead technology, but conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation (CD) markers for isolation and/or activation. After isolation of target immune cells and magnetic separation in the CTS DynaCellect system, the Gibco CTS Detachable Dynabeads Release Buffer is used to actively detach target cells from the CTS Dynabeads beads through a competitive binding mechanism. This flexible and scalable platform technology enables optimal isolation, activation, and purity, yield, desired phenotype, cell viability of subpopulations of T-cells.
Whether you are isolating CD4+ or CD8+ T-cell subtypes separately or in combination, you now can actively release the beads from target cells immediately after isolation using Gibco CTS Detachable Dynabeads CD4 and Gibco CTS Detachable Dynabeads CD8 products. No matter the workflow, when used with the Gibco CTS Detachable Dynabeads Release Buffer, both offerings are designed for increased control over target cell isolation and bead removal steps, compatibility with downstream genetic modification, high levels of pure T-cells free from ancillary material, and optimal target cell recovery for clinical trials or commercial manufacturing.
Figure 1. CD4+ and CD8+ T-cell purity using the CTS Detachable Dynabeads CD4 and CD8 products with the CTS DynaCellect Magnetic Separation System. Left panel: The variable starting material of three healthy donors (donors G, H, and I) contained an average 65% frequency of target T-cells. Right panel: The combined isolations achieved a high average purity of 99% of the target T-cells.
Gibco CTS Detachable Dynabeads CD3/CD28 magnetic beads are a flexible and scalable platform technology that helps enable isolation and activation in one step while possessing a differentiating active release mechanism. CTS Detachable Dynabeads CD3/CD28 has been found to be comparable to the passive detachable Dynabeads in IL-2 expression, activation marker profile, cytokine release panel, and cell proliferation levels. The key difference is the added release functionality to address biological variability and helps provide users with flexibility in their manufacturing process.
Figure 2A
Figure 2B
Figure 2. CTS Detachable Dynabeads CD3/CD28 induces similar expression of activation markers for A) CD69 and B) CD25 as the passive release CTS Dynabeads CD3/CD28. On days 2 and 3 post-activation, 94% to 98% of T-cells are expressing the CD25 activation marker, respectively.
Used in more than 100 clinical trials, Gibco CTS Dynabeads magnetic beads are a trusted technology for the isolation, activation, and/or expansion of T-cells ex vivo. Whether working with polyclonal T-cells, antigen-specific T-cells, gene-modified T-cells, regulatory T-cells, or other T-cell subtypes, CTS Dynabeads magnetic beads enable the recovery of T-cells with properties comparable to in vivo–activated T-cells. This one-step process of simultaneous T-cell isolation and activation yields pure and uniformly activated T-cells.
Figure 3. Activated T-cells typically expand >100-fold in 10 days. (A, B) Isolated and activated T-cells were expanded for up to 10 days, and both CD4+ and CD8+ T-cells proliferated. (C, D) On day 10 post-activation, there were mainly CD45RA+/– CD127+/– CD28+ CD62L+ cells with low PD-1 expression.
Gibco CTS Dynabeads Treg Xpander provides an optimized activation signal for activation and expansion of Regulatory T-cells (Tregs) and yields high-fold expansion of suppressive Tregs with a stable Treg phenotype, which is essential for use of Tregs in clinical applications.
Key features
Dynabeads Human T-Expander CD3/CD28, the research-grade version of CTS Dynabead CD3/CD28, is intended for separation, activation, and expansion of human T-cells. Containing the same amount and ratio of antibodies from the same clones as CTS Dynabeads CD3/CD28, Dynabeads Human T-Expander CD3/CD28 are intended for small-scale pre-clinical research. Dynabeads Human T-Expander CD3/CD28 offers a simple method for the activation and expansion of T-cells that does not require antigen presenting cells or antigen.
Whether you are isolating CD4+ or CD8+ T-cell subtypes separately or in combination, you now can actively release the beads from target cells immediately after isolation using Gibco CTS Detachable Dynabeads CD4 and Gibco CTS Detachable Dynabeads CD8 products. No matter the workflow, when used with the Gibco CTS Detachable Dynabeads Release Buffer, both offerings are designed for increased control over target cell isolation and bead removal steps, compatibility with downstream genetic modification, high levels of pure T-cells free from ancillary material, and optimal target cell recovery for clinical trials or commercial manufacturing.
Figure 1. CD4+ and CD8+ T-cell purity using the CTS Detachable Dynabeads CD4 and CD8 products with the CTS DynaCellect Magnetic Separation System. Left panel: The variable starting material of three healthy donors (donors G, H, and I) contained an average 65% frequency of target T-cells. Right panel: The combined isolations achieved a high average purity of 99% of the target T-cells.
Gibco CTS Detachable Dynabeads CD3/CD28 magnetic beads are a flexible and scalable platform technology that helps enable isolation and activation in one step while possessing a differentiating active release mechanism. CTS Detachable Dynabeads CD3/CD28 has been found to be comparable to the passive detachable Dynabeads in IL-2 expression, activation marker profile, cytokine release panel, and cell proliferation levels. The key difference is the added release functionality to address biological variability and helps provide users with flexibility in their manufacturing process.
Figure 2A
Figure 2B
Figure 2. CTS Detachable Dynabeads CD3/CD28 induces similar expression of activation markers for A) CD69 and B) CD25 as the passive release CTS Dynabeads CD3/CD28. On days 2 and 3 post-activation, 94% to 98% of T-cells are expressing the CD25 activation marker, respectively.
Used in more than 100 clinical trials, Gibco CTS Dynabeads magnetic beads are a trusted technology for the isolation, activation, and/or expansion of T-cells ex vivo. Whether working with polyclonal T-cells, antigen-specific T-cells, gene-modified T-cells, regulatory T-cells, or other T-cell subtypes, CTS Dynabeads magnetic beads enable the recovery of T-cells with properties comparable to in vivo–activated T-cells. This one-step process of simultaneous T-cell isolation and activation yields pure and uniformly activated T-cells.
Figure 3. Activated T-cells typically expand >100-fold in 10 days. (A, B) Isolated and activated T-cells were expanded for up to 10 days, and both CD4+ and CD8+ T-cells proliferated. (C, D) On day 10 post-activation, there were mainly CD45RA+/– CD127+/– CD28+ CD62L+ cells with low PD-1 expression.
Gibco CTS Dynabeads Treg Xpander provides an optimized activation signal for activation and expansion of Regulatory T-cells (Tregs) and yields high-fold expansion of suppressive Tregs with a stable Treg phenotype, which is essential for use of Tregs in clinical applications.
Key features
Dynabeads Human T-Expander CD3/CD28, the research-grade version of CTS Dynabead CD3/CD28, is intended for separation, activation, and expansion of human T-cells. Containing the same amount and ratio of antibodies from the same clones as CTS Dynabeads CD3/CD28, Dynabeads Human T-Expander CD3/CD28 are intended for small-scale pre-clinical research. Dynabeads Human T-Expander CD3/CD28 offers a simple method for the activation and expansion of T-cells that does not require antigen presenting cells or antigen.
Access a targeted collection of scientific application notes, case studies, posters, white papers and more for bioprocessing:
Intended use of the products mentioned on this page vary. For specific intended use statements please refer to the product label.